MTOR and renal cell adenocarcinoma: Several drugs have been developed for the treatment of RCC (see ‘Renal cell cancer pathway’); their targets include the vascular endothelial growth factor (VEGF) and its receptors downstream of Hif-mediated transcription or the mTOR pathway which regulates HIF translation [35].